The collection of high-quality endpoint data was paramount to the success of this Phase II program. Because this was the first clinical trial ever done for this disease, it was necessary to develop non- disease-specific clinical assessments, in collaboration with Key Opinion Leaders (KOLs), for use as endpoints. The newness of these tools presented challenges to site selection and training, as well as risks to uniformity in patient recruitment and consistency in data collection.
PRA Successfully Delivers A Complex Phase I Psoriasis Study
Exceptional Support and Innovative Strategies Combat Study Challenges.
Alzheimer's Disease Research 2018
PRA conducted a survey at the 2018 Alzheimer's Association International Conference in Chicago. Across the board we found that the research community…
Clinical Trial Manager
A PRA Clinical Trial Manager leads and manages the execution of one or more clinical studies from study startup through database release. As a core…